What is Derma Sensor?
Derma Sensor Inc. is a health technology innovator focused on empowering primary care providers with advanced, non-invasive tools for skin cancer screenings. Their flagship device employs machine learning and spectroscopy to rapidly assess skin lesions, aiming to improve patient outcomes and reduce healthcare expenditures by increasing access to early detection. The company's objective is to make effective skin cancer checks more widely available, as a significant portion of the population currently foregoes annual screenings. The DermaSensor device has achieved CE Mark and is available in Australia and New Zealand, with plans for broader market clearance.
How much funding has Derma Sensor raised?
Derma Sensor has raised a total of $21.8M across 4 funding rounds:
Debt
$150K
Series A
$11.5M
Debt
$162K
Other Financing Round
$10M
Debt (2020): $150K with participation from PPP
Series A (2020): $11.5M led by Dr. Maurice R. Ferre, David Matlin, Chris Dewey, and SternAegis Ventures
Debt (2021): $162K supported by PPP
Other Financing Round (2022): $10M featuring Ceros Capital Markets
Key Investors in Derma Sensor
Ceros Capital Markets
Ceros Capital Markets is a global investing platform that specializes in fundraising for MedTech and Biotech companies, focusing on disruptive technologies in medical devices, robotics, and digital health. The firm primarily raises funds through Series A-D rounds for innovative companies developing non-invasive diagnostic procedures. Ceros aims to connect sophisticated investors with early-stage ventures that enhance healthcare efficiency and patient care while reducing industry costs. Their client base includes institutional investors looking to invest in groundbreaking technologies that are transforming the medical industry.
SternAegis Ventures
SternAegis Ventures specializes in principal investing, investment banking, merchant banking, and strategic consulting services. The company aims to accelerate growth and unlock value for its clients, which include qualified small businesses. They offer brokerage and investment advisory products through Aegis Capital Corp, and insurance products via ACC General Agency. SternAegis Ventures emphasizes the importance of professional advice for investment decisions, highlighting the associated risks and considerations.
Dr. Maurice R. Ferre
Undisclosed investor participating in the funding round.
What's next for Derma Sensor?
The substantial enterprise-level funding positions Derma Sensor for significant scaling and market expansion. This capital injection is expected to accelerate the company's efforts to obtain regulatory clearance in additional key markets and enhance its manufacturing capabilities. The strategic nature of the recent investment suggests a focus on strengthening partnerships and optimizing the go-to-market strategy. Derma Sensor is poised to become a leader in accessible dermatological diagnostics, driving efficiency in primary care and improving patient health outcomes through early detection.
See full Derma Sensor company page
